Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.

Several proteins, including transforming growth factor beta (TGF-beta) receptor type I (RI), TGF-beta receptor type II (RII), Smad2, Smad3, and Smad4/DPC4, have been identified in the transduction pathway of the tumor suppressor TGF-beta. Mutations in TGF-beta RI, TGF-beta RII, Smad2, and Smad4/DPC4 genes are associated with several human cancers. The present study examines these gene mutations in 32 human ovarian cancers and 14 patient-matched normal tissues. For the first time, mutations in the Smad2 and Smad4 genes were analyzed in relation to human ovarian cancer. Gene mutations of TGF-beta RI, TGF-beta RII, Smad2, and Smad4 were analyzed using specific primers by PCR-single-strand conformational polymorphism (SSCP), and the results revealed a frameshift mutation at codons 276-277 (CTCTGG-->CTGCGTGG) in exon 5 of TGF-beta RI in 10 of 32 tumor samples (31.3%). This mutation was associated with reduced or absent expression of TGF-beta RI protein and p53 protein in tumor tissues. We detected SSCP variants of TGF-beta RII in exon 2 in 20 of 32 tumors. Sequence analysis of these variants revealed an A to G transition at the seventh band of intron 2. In this A to G polymorphism in intron 2, 12 samples (37.5%) had A/A alleles, 12 (37.5%) had A/G alleles, and 8 (25%) had G/G alleles. We detected Smad2 SSCP variants in exon 4 in 12 of 32 tumors (37.5%). Sequence analysis revealed a 2-bp deletion in the polypyrimidine tract of intron 3, which is located at position -39 to -56 in the splice acceptor site of the intron 3-exon 4 junction. No SSCP variants were detected in the Smad4 gene. These findings suggest that mutations in the TGF-beta RI and in its signal transduction pathway are likely responsible for human ovarian carcinogenesis.

[1]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[2]  C. J. Gimeno,et al.  Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Harris,et al.  Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles. , 1997, Carcinogenesis.

[4]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[5]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[6]  Chung Lee,et al.  Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .

[7]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[8]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[9]  T. Enomoto,et al.  Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. , 1998, Cancer research.

[10]  J. Massagué.  TGFβ Signaling: Receptors, Transducers, and Mad Proteins , 1996, Cell.

[11]  C. Garrett,et al.  Protooncogene amplification and tumor ploidy in human ovarian neoplasms. , 1990, Human pathology.

[12]  P. Hoodless,et al.  MADR1, a MAD-Related Protein That Functions in BMP2 Signaling Pathways , 1996, Cell.

[13]  M. Reiss,et al.  Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. , 1993, Cancer research.

[14]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[15]  M. Garcia-Blanco,et al.  A mutational analysis of the polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing. , 1993, The Journal of biological chemistry.

[16]  J. Manley,et al.  The role of the polypyrimidine stretch at the SV40 early pre‐mRNA 3′ splice site in alternative splicing. , 1988, The EMBO journal.

[17]  K. Kinzler,et al.  Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.

[18]  R. Derynck,et al.  Receptor-associated Mad homologues synergize as effectors of the TGF-β response , 1996, Nature.

[19]  K. Miyazono,et al.  Enhanced expression of transforming growth factor‐β and its type‐I and type‐II receptors in human glioblastoma , 1995, International journal of cancer.

[20]  M. Modan,et al.  Possible role of mumps virus in the etiology of ovarian cancer , 1979, Cancer.

[21]  J. Massagué,et al.  Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways , 1996, Nature.

[22]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[23]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[24]  E. Wynder,et al.  International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption , 1986 .

[25]  S. Thorgeirsson,et al.  Induction of p53 and Bax during TGF-beta 1 initiated apoptosis in rat liver epithelial cells. , 1998, Biochemical and biophysical research communications.

[26]  P. Norton,et al.  Polypyrimidine tract sequences direct selection of alternative branch sites and influence protein binding. , 1994, Nucleic acids research.

[27]  J. Yokota,et al.  Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and Intron primers , 1997, Oncogene.

[28]  P. Hoodless,et al.  MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.

[29]  I. Andersson,et al.  Reexamination of the Three-Dimensional Structure of the Small Subunit of RuBisCo from Higher Plants , 1989, Science.

[30]  Robert F. RoscignoSBlI,et al.  A Mutational Analysis of the Polypyrimidine Tract of Introns , 1993 .

[31]  Kathleen R. Cho,et al.  A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. , 1995, Cancer research.

[32]  A. Harris.  Mutant p53—the commonest genetic abnormality in human cancer? , 1990, The Journal of pathology.

[33]  D. Kingsley,et al.  The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. , 1994, Genes & development.

[34]  H. Yokozaki,et al.  Expression of TGF‐β and procollagen type I and type III in human gastric carcinomas , 1989 .

[35]  K. Hatch,et al.  Oncogene alterations in endometrial carcinoma. , 1990, Gynecologic oncology.

[36]  P Chambon,et al.  Isolation of high-molecular-weight DNA from mammalian cells. , 1973, European journal of biochemistry.

[37]  T. Moody,et al.  Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation. , 1997, Anticancer research.

[38]  K. Kinzler,et al.  Frequency of Smad gene mutations in human cancers. , 1997, Cancer research.

[39]  H. Lodish,et al.  Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia , 1997 .

[40]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[41]  T. Mitsudomi,et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[42]  D. Longo,et al.  COSMETIC TALC AND OVARIAN CANCER , 1979, The Lancet.

[43]  R. Bast,et al.  Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. , 1995, Cancer research.

[44]  S. Takenoshita,et al.  Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas. , 1998, International journal of oncology.

[45]  J. Yokota,et al.  Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers. , 1998, Carcinogenesis.